title: Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease.
abstract: Cerebral accumulation of beta-amyloid peptide (A beta) is a central event in the pathogenesis of Alzheimer's disease (AD). Endothelin-converting enzyme-1 (ECE-1) is a candidate A beta-degrading enzyme in brain, but its involvement in AD pathogenesis was never assessed. We first performed brain immunocytochemistry, using a monoclonal anti-ECE-1 antibody, and observed neuronal ECE-1 expression in various cortical regions of nondemented subjects. In the hippocampus, ECE-1 immunoreactivity showed a stereotypical pattern inversely correlated with susceptibility to A beta deposition, further suggesting a physiological role in A beta clearance. In order to undertake a genetic association study, we identified a functional genetic variant (ECE1B C-338A) located in a regulatory region of the ECE1 gene. We showed that the A allele is associated with increased transcriptional activity in promoter-reporter gene assays and with increased ECE-1 mRNA expression in human neocortex. In a case-control study involving 401 patients with late-onset AD and 461 aged controls, we found that homozygous carriers of the A allele had a reduced risk of AD (OR=0.47, 95% CI 0.25-0.88). This finding was strengthened by the analysis of two other genetic variants of the ECE1 gene, which showed that the genetic association is extended over at least 13 kilobases of the gene sequence. Our results suggest that ECE-1 expression in brain may be critical for cortical A beta clearance and offer new potential targets for therapeutic interventions in AD.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale Unit 573, 75014 Paris, France. benoit.funalot@broca.inserm.fr
authors.forename: B
authors.initials: B
authors.lastname: Funalot
authors.forename: T
authors.initials: T
authors.lastname: Ouimet
authors.forename: A
authors.initials: A
authors.lastname: Claperon
authors.forename: C
authors.initials: C
authors.lastname: Fallet
authors.forename: A
authors.initials: A
authors.lastname: Delacourte
authors.forename: J
authors.initials: J
authors.lastname: Epelbaum
authors.forename: T
authors.initials: T
authors.lastname: Subkowski
authors.forename: N
authors.initials: N
authors.lastname: Léonard
authors.forename: V
authors.initials: V
authors.lastname: Codron
authors.forename: J-P
authors.initials: JP
authors.lastname: David
authors.forename: P
authors.initials: P
authors.lastname: Amouyel
authors.forename: J-C
authors.initials: JC
authors.lastname: Schwartz
authors.forename: N
authors.initials: N
authors.lastname: Helbecque
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000201:enzymology* / Q000235:genetics; D016229:Amyloid beta-Peptides / Q000378:metabolism; D016282:Aspartic Acid Endopeptidases / Q000235:genetics* / Q000378:metabolism*; D016022:Case-Control Studies; D002540:Cerebral Cortex / Q000166:cytology / Q000378:metabolism*; D000072396:Endothelin-Converting Enzymes; D020022:Genetic Predisposition to Disease; D006624:Hippocampus / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008666:Metalloendopeptidases; D009474:Neurons / Q000378:metabolism*; D012016:Reference Values; D012307:Risk Factors; D014018:Tissue Distribution
chemical_list: D016229:Amyloid beta-Peptides; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; C000606923:ECE1 protein, human; D000072396:Endothelin-Converting Enzymes